公开(公告)号：WO2011159892A1

公开(公告)日：2011-12-22

申请号：PCT/US2011/040695

申请日：2011-06-16

Applicant: AMERICAN MEGATRENDS, INC. ,  YAKOVLEV, Sergiy, B.

Inventor： YAKOVLEV, Sergiy, B.

IPC: G06F13/00

CPC classification number: G06F13/24 ,  G06F13/102 ,  G06F2213/0024

Abstract: Technologies are provided herein for multiple platform support in a computer system firmware. A firmware is built for each hardware platform to be supported. At built time of the firmware for each platform to be supported, an instance of platform specific information is extracted from the built firmware and stored. Once the platform specific information instances have been collected for each platform to be supported, the platform specific information instances are stored in a multi-platform firmware. At run-time of the multi-platform firmware, the particular hardware platform that the multi-platform firmware is executing upon is identified. Once the platform has been identified, the particular instance of platform specific information corresponding to the identified platform is selected. The selected instance of platform specific information is then loaded and exposed for consumption by other programs.

Abstract translation: 本文提供了在计算机系统固件中进行多平台支持的技术。 为每个要支持的硬件平台构建固件。 在支持每个平台的固件的内置时间，从构建的固件中提取平台特定信息的实例并存储。 一旦为需要支持的每个平台收集了平台特定信息实例，平台特定信息实例就被存储在多平台固件中。 在多平台固件运行时，确定了多平台固件正在执行的特定硬件平台。 一旦该平台被识别，则选择与所识别的平台对应的平台特定信息的特定实例。 所选择的平台特定信息的实例然后被加载和公开以供其他程序消费。

公开(公告)号：WO2009038729A2

公开(公告)日：2009-03-26

申请号：PCT/US2008/010832

申请日：2008-09-17

Applicant: RegeneRx Biopharmaceuticals, Inc. ,  University Of Maryland, Baltimore ,  MEDVED, Leonid ,  ZHANG, Li ,  YAKOVLEV, Sergiy ,  GOLDSTEIN, Allan L. ,  CROCKFORD, David

Inventor： MEDVED, Leonid ,  ZHANG, Li ,  YAKOVLEV, Sergiy ,  GOLDSTEIN, Allan L. ,  CROCKFORD, David

IPC: C12N9/68

CPC classification number: C07K14/75

Abstract: A composition including a peptide sequence of the formula βX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type β15-42 monomer sequence per se, and wherein the peptide sequence is other than (β15-66) 2 dimer having two chains with each chain limited to wild type amino acids β15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4. In such methods and combinations, a dimer of the peptide sequence may include amino acids 15-66 of the fibrin beta chain.

Abstract translation: 一种组合物，其包含式ßX1-X2的肽序列，所述肽序列对应于纤维蛋白原Bbeta链的纤维蛋白β链片段的氨基酸序列，其中X1表示肽序列的N末端，X2 表示肽序列的C-末端，其中所述肽序列包括X1和X2之间的另外的氨基酸，其中所述肽序列可以含有非天然存在的氨基酸残基，其中所述肽序列不是野生型 ß15-42单体序列本身，并且其中所述肽序列不同于具有两条链的（ß15-66）2二聚体，每条链限于野生型氨基酸ß15-65，并且每条链还包含非天然存在的Gly 每个链的位置66。 用于治疗和药物组合的方法可以包括多肽试剂例如胸腺素β4。在这些方法和组合中，肽序列的二聚体可以包括纤维蛋白β链的氨基酸15-66。

公开(公告)号：WO2017210539A1

公开(公告)日：2017-12-07

申请号：PCT/US2017/035654

申请日：2017-06-02

Applicant: UNIVERSITY OF MARYLAND, BALTIMORE ,  MEDVED, Leonid, V. ,  STRICKLAND, Dudley ,  YAKOVLEV, Sergiy

Inventor： MEDVED, Leonid, V. ,  STRICKLAND, Dudley ,  YAKOVLEV, Sergiy

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/00 ,  C12P21/08 ,  A61K38/00 ,  A61K38/36

CPC classification number: A61K38/1774 ,  A61K38/363 ,  A61K2039/505 ,  A61P9/10 ,  A61P37/06 ,  C07K16/28 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The invention provides a method of treating inflammation, comprising administering to a subject in need thereof a therapeutically effective amount of an agent that inhibits binding of fibrin to Very Low Density Lipoprotein Receptor (VLDLR) or combination of this agent with agents inhibiting binding of fibrin to VE- cahherin (vascular endothelial cadherin).

Abstract translation: 本发明提供了治疗炎症的方法，其包括向有需要的受试者施用治疗有效量的抑制纤维蛋白与极低密度脂蛋白受体（VLDLR）结合的试剂或其组合 试剂与抑制纤维蛋白与VE-钙粘蛋白（血管内皮钙粘蛋白）结合的试剂。

公开(公告)号：WO2009038729A3

公开(公告)日：2009-12-30

申请号：PCT/US2008010832

申请日：2008-09-17

Applicant: REGENERX BIOPHARMACEUTICALS ,  UNIV MARYLAND ,  MEDVED LEONID ,  ZHANG LI ,  YAKOVLEV SERGIY ,  GOLDSTEIN ALLAN L ,  CROCKFORD DAVID

Inventor： MEDVED LEONID ,  ZHANG LI ,  YAKOVLEV SERGIY ,  GOLDSTEIN ALLAN L ,  CROCKFORD DAVID

IPC: A61K38/16 ,  C07K14/435

CPC classification number: C07K14/75

Abstract: A composition including a peptide sequence of the formula ßX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type ß15-42 monomer sequence per se, and wherein the peptide sequence is other than (ß15-66)2 dimer having two chains with each chain limited to wild type amino acids ß15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4. In such methods and combinations, a dimer of the peptide sequence may include amino acids 15-66 of the fibrin beta chain.

Abstract translation: 一种组合物，其包含式X 1 -X 2的肽序列，所述肽序列对应于纤维蛋白原的Bβ链的纤维蛋白β链片段的氨基酸序列，其中X 1代表所述肽序列的N-末端，并且X 2 代表肽序列的C-末端，其中所述肽序列包含X1和X2之间的额外氨基酸，其中所述肽序列可含有非天然存在的氨基酸残基，其中所述肽序列不是野生型 其中所述肽序列不是具有两条链的（β15-66）2二聚体，其中每条链限于野生型氨基酸β15-65，并且每条链还包含非天然存在的Gly 每个链的位置66。 用于治疗和药物组合的方法可以包括多肽试剂，例如胸腺素β4。在这样的方法和组合中，肽序列的二聚体可以包括纤维蛋白β链的氨基酸15-66。